Cargando…

Extensive sequence and structural evolution of Arginase 2 inhibitory antibodies enabled by an unbiased approach to affinity maturation

Affinity maturation is a powerful technique in antibody engineering for the in vitro evolution of antigen binding interactions. Key to the success of this process is the expansion of sequence and combinatorial diversity to increase the structural repertoire from which superior binding variants may b...

Descripción completa

Detalles Bibliográficos
Autores principales: Chan, Denice T. Y., Jenkinson, Lesley, Haynes, Stuart W., Austin, Mark, Diamandakis, Agata, Burschowsky, Daniel, Seewooruthun, Chitra, Addyman, Alexandra, Fiedler, Sebastian, Ryman, Stephanie, Whitehouse, Jessica, Slater, Louise H., Gowans, Ellen, Shibata, Yoko, Barnard, Michelle, Wilkinson, Robert W., Vaughan, Tristan J., Holt, Sarah V., Cerundolo, Vincenzo, Carr, Mark D., Groves, Maria A. T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: National Academy of Sciences 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7382286/
https://www.ncbi.nlm.nih.gov/pubmed/32616569
http://dx.doi.org/10.1073/pnas.1919565117
_version_ 1783563215945334784
author Chan, Denice T. Y.
Jenkinson, Lesley
Haynes, Stuart W.
Austin, Mark
Diamandakis, Agata
Burschowsky, Daniel
Seewooruthun, Chitra
Addyman, Alexandra
Fiedler, Sebastian
Ryman, Stephanie
Whitehouse, Jessica
Slater, Louise H.
Gowans, Ellen
Shibata, Yoko
Barnard, Michelle
Wilkinson, Robert W.
Vaughan, Tristan J.
Holt, Sarah V.
Cerundolo, Vincenzo
Carr, Mark D.
Groves, Maria A. T.
author_facet Chan, Denice T. Y.
Jenkinson, Lesley
Haynes, Stuart W.
Austin, Mark
Diamandakis, Agata
Burschowsky, Daniel
Seewooruthun, Chitra
Addyman, Alexandra
Fiedler, Sebastian
Ryman, Stephanie
Whitehouse, Jessica
Slater, Louise H.
Gowans, Ellen
Shibata, Yoko
Barnard, Michelle
Wilkinson, Robert W.
Vaughan, Tristan J.
Holt, Sarah V.
Cerundolo, Vincenzo
Carr, Mark D.
Groves, Maria A. T.
author_sort Chan, Denice T. Y.
collection PubMed
description Affinity maturation is a powerful technique in antibody engineering for the in vitro evolution of antigen binding interactions. Key to the success of this process is the expansion of sequence and combinatorial diversity to increase the structural repertoire from which superior binding variants may be selected. However, conventional strategies are often restrictive and only focus on small regions of the antibody at a time. In this study, we used a method that combined antibody chain shuffling and a staggered-extension process to produce unbiased libraries, which recombined beneficial mutations from all six complementarity-determining regions (CDRs) in the affinity maturation of an inhibitory antibody to Arginase 2 (ARG2). We made use of the vast display capacity of ribosome display to accommodate the sequence space required for the diverse library builds. Further diversity was introduced through pool maturation to optimize seven leads of interest simultaneously. This resulted in antibodies with substantial improvements in binding properties and inhibition potency. The extensive sequence changes resulting from this approach were translated into striking structural changes for parent and affinity-matured antibodies bound to ARG2, with a large reorientation of the binding paratope facilitating increases in contact surface and shape complementarity to the antigen. The considerable gains in therapeutic properties seen from extensive sequence and structural evolution of the parent ARG2 inhibitory antibody clearly illustrate the advantages of the unbiased approach developed, which was key to the identification of high-affinity antibodies with the desired inhibitory potency and specificity.
format Online
Article
Text
id pubmed-7382286
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher National Academy of Sciences
record_format MEDLINE/PubMed
spelling pubmed-73822862020-07-30 Extensive sequence and structural evolution of Arginase 2 inhibitory antibodies enabled by an unbiased approach to affinity maturation Chan, Denice T. Y. Jenkinson, Lesley Haynes, Stuart W. Austin, Mark Diamandakis, Agata Burschowsky, Daniel Seewooruthun, Chitra Addyman, Alexandra Fiedler, Sebastian Ryman, Stephanie Whitehouse, Jessica Slater, Louise H. Gowans, Ellen Shibata, Yoko Barnard, Michelle Wilkinson, Robert W. Vaughan, Tristan J. Holt, Sarah V. Cerundolo, Vincenzo Carr, Mark D. Groves, Maria A. T. Proc Natl Acad Sci U S A Biological Sciences Affinity maturation is a powerful technique in antibody engineering for the in vitro evolution of antigen binding interactions. Key to the success of this process is the expansion of sequence and combinatorial diversity to increase the structural repertoire from which superior binding variants may be selected. However, conventional strategies are often restrictive and only focus on small regions of the antibody at a time. In this study, we used a method that combined antibody chain shuffling and a staggered-extension process to produce unbiased libraries, which recombined beneficial mutations from all six complementarity-determining regions (CDRs) in the affinity maturation of an inhibitory antibody to Arginase 2 (ARG2). We made use of the vast display capacity of ribosome display to accommodate the sequence space required for the diverse library builds. Further diversity was introduced through pool maturation to optimize seven leads of interest simultaneously. This resulted in antibodies with substantial improvements in binding properties and inhibition potency. The extensive sequence changes resulting from this approach were translated into striking structural changes for parent and affinity-matured antibodies bound to ARG2, with a large reorientation of the binding paratope facilitating increases in contact surface and shape complementarity to the antigen. The considerable gains in therapeutic properties seen from extensive sequence and structural evolution of the parent ARG2 inhibitory antibody clearly illustrate the advantages of the unbiased approach developed, which was key to the identification of high-affinity antibodies with the desired inhibitory potency and specificity. National Academy of Sciences 2020-07-21 2020-07-02 /pmc/articles/PMC7382286/ /pubmed/32616569 http://dx.doi.org/10.1073/pnas.1919565117 Text en https://creativecommons.org/licenses/by/4.0/This open access article is distributed under Creative Commons Attribution License 4.0 (CC BY) (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Biological Sciences
Chan, Denice T. Y.
Jenkinson, Lesley
Haynes, Stuart W.
Austin, Mark
Diamandakis, Agata
Burschowsky, Daniel
Seewooruthun, Chitra
Addyman, Alexandra
Fiedler, Sebastian
Ryman, Stephanie
Whitehouse, Jessica
Slater, Louise H.
Gowans, Ellen
Shibata, Yoko
Barnard, Michelle
Wilkinson, Robert W.
Vaughan, Tristan J.
Holt, Sarah V.
Cerundolo, Vincenzo
Carr, Mark D.
Groves, Maria A. T.
Extensive sequence and structural evolution of Arginase 2 inhibitory antibodies enabled by an unbiased approach to affinity maturation
title Extensive sequence and structural evolution of Arginase 2 inhibitory antibodies enabled by an unbiased approach to affinity maturation
title_full Extensive sequence and structural evolution of Arginase 2 inhibitory antibodies enabled by an unbiased approach to affinity maturation
title_fullStr Extensive sequence and structural evolution of Arginase 2 inhibitory antibodies enabled by an unbiased approach to affinity maturation
title_full_unstemmed Extensive sequence and structural evolution of Arginase 2 inhibitory antibodies enabled by an unbiased approach to affinity maturation
title_short Extensive sequence and structural evolution of Arginase 2 inhibitory antibodies enabled by an unbiased approach to affinity maturation
title_sort extensive sequence and structural evolution of arginase 2 inhibitory antibodies enabled by an unbiased approach to affinity maturation
topic Biological Sciences
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7382286/
https://www.ncbi.nlm.nih.gov/pubmed/32616569
http://dx.doi.org/10.1073/pnas.1919565117
work_keys_str_mv AT chandenicety extensivesequenceandstructuralevolutionofarginase2inhibitoryantibodiesenabledbyanunbiasedapproachtoaffinitymaturation
AT jenkinsonlesley extensivesequenceandstructuralevolutionofarginase2inhibitoryantibodiesenabledbyanunbiasedapproachtoaffinitymaturation
AT haynesstuartw extensivesequenceandstructuralevolutionofarginase2inhibitoryantibodiesenabledbyanunbiasedapproachtoaffinitymaturation
AT austinmark extensivesequenceandstructuralevolutionofarginase2inhibitoryantibodiesenabledbyanunbiasedapproachtoaffinitymaturation
AT diamandakisagata extensivesequenceandstructuralevolutionofarginase2inhibitoryantibodiesenabledbyanunbiasedapproachtoaffinitymaturation
AT burschowskydaniel extensivesequenceandstructuralevolutionofarginase2inhibitoryantibodiesenabledbyanunbiasedapproachtoaffinitymaturation
AT seewooruthunchitra extensivesequenceandstructuralevolutionofarginase2inhibitoryantibodiesenabledbyanunbiasedapproachtoaffinitymaturation
AT addymanalexandra extensivesequenceandstructuralevolutionofarginase2inhibitoryantibodiesenabledbyanunbiasedapproachtoaffinitymaturation
AT fiedlersebastian extensivesequenceandstructuralevolutionofarginase2inhibitoryantibodiesenabledbyanunbiasedapproachtoaffinitymaturation
AT rymanstephanie extensivesequenceandstructuralevolutionofarginase2inhibitoryantibodiesenabledbyanunbiasedapproachtoaffinitymaturation
AT whitehousejessica extensivesequenceandstructuralevolutionofarginase2inhibitoryantibodiesenabledbyanunbiasedapproachtoaffinitymaturation
AT slaterlouiseh extensivesequenceandstructuralevolutionofarginase2inhibitoryantibodiesenabledbyanunbiasedapproachtoaffinitymaturation
AT gowansellen extensivesequenceandstructuralevolutionofarginase2inhibitoryantibodiesenabledbyanunbiasedapproachtoaffinitymaturation
AT shibatayoko extensivesequenceandstructuralevolutionofarginase2inhibitoryantibodiesenabledbyanunbiasedapproachtoaffinitymaturation
AT barnardmichelle extensivesequenceandstructuralevolutionofarginase2inhibitoryantibodiesenabledbyanunbiasedapproachtoaffinitymaturation
AT wilkinsonrobertw extensivesequenceandstructuralevolutionofarginase2inhibitoryantibodiesenabledbyanunbiasedapproachtoaffinitymaturation
AT vaughantristanj extensivesequenceandstructuralevolutionofarginase2inhibitoryantibodiesenabledbyanunbiasedapproachtoaffinitymaturation
AT holtsarahv extensivesequenceandstructuralevolutionofarginase2inhibitoryantibodiesenabledbyanunbiasedapproachtoaffinitymaturation
AT cerundolovincenzo extensivesequenceandstructuralevolutionofarginase2inhibitoryantibodiesenabledbyanunbiasedapproachtoaffinitymaturation
AT carrmarkd extensivesequenceandstructuralevolutionofarginase2inhibitoryantibodiesenabledbyanunbiasedapproachtoaffinitymaturation
AT grovesmariaat extensivesequenceandstructuralevolutionofarginase2inhibitoryantibodiesenabledbyanunbiasedapproachtoaffinitymaturation